MedTrace Logo

Evaluation of Universal Rotavirus Vaccination Program

NCT01273077 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 12705

Last updated 2022-02-04

No results posted yet for this study

Summary

Two rotavirus vaccines have been authorized for use in Canada: RotaTeq®, Merck Frost Canada, Inc. and Rotarix®, Glaxo Smith Kline (GSK). In contrast to the United States, Australia and several other western countries, neither rotavirus vaccine is offered in a publicly funded program in Canada. A universal rotavirus immunization program offered to all children has the potential to prevent moderate to severe forms of the disease associated with rotavirus, with associated decreased disease burden and health care costs. This demonstration project seeks to evaluate the effect of the implementation of a universal infant immunization program with Rotarix employing two different program delivery models (public health delivery or physician office delivery) in comparison to a jurisdiction where routine immunization is not provided. Only evaluation of the program will be the subject of this study.

Conditions

  • Gastrointestinal Diseases

Sponsors & Collaborators

  • IWK Health Centre

    collaborator OTHER

  • University of Prince Edward Island

    collaborator OTHER

  • Horizon Health Care New Brunswick

    collaborator UNKNOWN

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Nova Scotia Health Authority

    collaborator OTHER

  • Dalhousie University

    lead OTHER

Principal Investigators

  • Donna MacDougall, PhD, RN · Canadian Center for Vaccinology

Eligibility

Min Age
6 Weeks
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2013-07-31
Completion
2013-07-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01273077 on ClinicalTrials.gov